Prostate Cancer Clinical Trials

Showing 1981-2000 of 2,150 trials

Vaccine Therapy Plus QS21 in Treating Patients With Progressive Prostate Cancer

NCT00004929

RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. PURPOSE: Phase II trial to study the effectiveness of vaccine therapy given with QS21 in treating patients who have progressive prostate cancer.

Prostate Cancer

Memorial Sloan Kettering Cancer Center15 participantsStarted Sep 1999

New York, New York, United States

TERMINATEDPhase 2

A Phase II Trial of Calcitriol and Naproxen in Patients With Recurrent Prostate Cancer

NCT00383487

To determine whether, in this patient population, treatment with calcitriol and Naproxen is more effective in delaying the growth of prostate cancer than treatment with calcitriol alone as seen in historical controls.

Prostatic NeoplasmsProstate Cancer

Stanford University20 participantsStarted Mar 2005

Stanford, California, United States

COMPLETEDPhase 2

SB-715992 in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Docetaxel or Paclitaxel

NCT00096499

Drugs used in chemotherapy, such as SB-715992, work in different ways to stop tumor cells from dividing so they stop growing or die. This phase II trial is studying how well SB-715992 works in treating patients with metastatic prostate cancer that did not respond to docetaxel or paclitaxel

Adenocarcinoma of the ProstateRecurrent Prostate CancerStage IV Prostate Cancer

National Cancer Institute (NCI)40 participantsStarted Apr 2005

San Antonio, Texas, United States

COMPLETEDPhase 2

Vaccine Therapy in Treating Patients With Recurrent Prostate Cancer

NCT00109811

This phase II trial is studying how well vaccine therapy works in treating patients with recurrent prostate cancer. Vaccines made from peptides may help the body build an effective immune response to kill tumor cells

Adenocarcinoma of the ProstateRecurrent Prostate Cancer

National Cancer Institute (NCI)32 participantsStarted Mar 2005

Baltimore, Maryland, United States

Vaccine Therapy Plus QS21 in Treating Patients With Progressive Prostate Cancer

A Phase II Trial of Calcitriol and Naproxen in Patients With Recurrent Prostate Cancer

SB-715992 in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Docetaxel or Paclitaxel

Vaccine Therapy in Treating Patients With Recurrent Prostate Cancer

Related Searches

ET 743 (Yondelis) in Men With Advanced Prostate Cancer

Testosterone in Treating Patients With Progressive Prostate Cancer That No Longer Responds to Hormone Therapy

Degarelix as Second-Line Hormonal Treatment After Prostate-specific Antigen (PSA)-Failure in GnRH Agonist Treated Patients With Prostate Cancer

Safety and Effectiveness of a Vaccine for Prostate Cancer That Uses Each Patients' Own Immune Cells.

Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction

Docetaxel in Treating Older Patients With Metastatic Breast, Lung, or Prostate Cancer

Participation in Procurement of Tissue, Serum, Plasma, Cell Bank, DNA and RNA Samples, and Urine for Biological Studies Related to Prostate Cancer and Prostate Cancer Treatment Follow Up

Monoclonal Antibody ABX-EGF in Treating Patients With Renal (Kidney), Prostate, Pancreatic, Non-Small Cell Lung, Colon or Rectal, Esophageal, or Gastroesophageal Junction Cancer

Efficacy of Prostate Seed Implantation for Local Control of Early Stage Prostate Cancer

Study of SU11248 in Men With Advanced Prostate Cancer

The Efficacy and Safety of Degarelix One Month Dosing Regimens in Prostate Cancer

Internet-Based Education for Prostate Cancer Screening

Acceptance-Based Treatment for Prostate Cancer Distress

Immune Profiles and Circulating Tumor Cell Status Following Prostate Cryotherapy

Red Yeast Rice in Subjects With Clinically Localized Prostate Cancer Undergoing Active Surveillance

Vaccine Therapy in Treating Patients With Metastatic, Progressive Prostate Cancer